Molson Coors Inks Exclusive Deal With Coca-Cola To Launch Simply Spiked Lemonade - Quick Facts

Molson Coors Beverage Co. (TAP) announce Tuesday it has expanded its exclusive agreement with The Coca-Cola Co. (KO) to develop and commercialize a brand of full-flavor alcohol beverages inspired by the country's leading chilled juice brand, Simply.

Molson Coors will produce, distribute and market Simply Spiked Lemonade as part of an agreement with Coca-Cola.

The deal marks another milestone in the relationship between Molson Coors and Coca-Cola, following a successful first year for Topo Chico Hard Seltzer.

This summer, Molson Coors will start by launching the Simply Spiked Lemonade variety pack, inspired by some of Simply's best-selling non-alcoholic products, including Strawberry Lemonade, Watermelon Lemonade, Blueberry Lemonade and, of course, Signature Lemonade.

The bold, great-tasting flavors of the Simply brand mix seamlessly with alcohol for cocktails, which inspired the ready-to-drink lineup. Simply Spiked Lemonade will be sold in slim-can 12pks as a variety pack, and 24oz standalone cans of select flavors.

Simply Spiked Lemonade and the national expansion of Topo Chico Hard Seltzer mark the latest initiatives to aggressively grow Molson Coors' above premium portfolio as part of the company's revitalization plan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT